CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 8,941	$ 6,171
General and administrative	4,789	1,707
Total operating expenses	13,730	7,878
Loss from operations	(13,730)	(7,878)
Other income:
Interest income	7	29
Total other income	7	29
Net loss and comprehensive loss	(13,723)	(7,849)
Cumulative dividends on redeemable convertible preferred stock	(1,228)	(715)
Net loss attributable to common stockholders	$ (14,951)	$ (8,564)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.67)	$ (59.06)
Weighted-average common shares outstanding, basic and diluted	22,263,994	145,016